Clinical trial
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head…
NCT00425750 · Vanderbilt-Ingram Cancer Center, Other · Completed
Key facts
| NCT number | NCT00425750 |
|---|---|
| Title | Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| Official title | Phase II Trial of Combination Weekly Bortezomib (VELCADE) and Docetaxel (TAXOTERE) in Patients With Recurrent and/ or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, docetaxel, laboratory biomarker analysis, pharmacological study |
| Enrollment | 25 |
| Start date | Aug 1, 2005 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 23, 2007 |
| Last update posted | Nov 16, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: